Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, Keswani A, Webber KC, Montgomery-Recht K, Walkiewicz M, Notarangelo LD, Burbelo PD, Fuss I, Cohen JI, Bollard CM, Keller MD. Kinoshita H, et al. Among authors: jensen wachspress m. J Clin Immunol. 2021 Aug;41(6):1146-1153. doi: 10.1007/s10875-021-01046-y. Epub 2021 May 13. J Clin Immunol. 2021. PMID: 33983545 Free PMC article.
SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection.
Conway SR, Lazarski CA, Field NE, Jensen-Wachspress M, Lang H, Kankate V, Durkee-Shock J, Kinoshita H, Suslovic W, Webber K, Smith K, Cohen JI, Burbelo PD, Zhang A, Teach SJ, Ibeh T, Delaney M, DeBiasi RL, Keller MD, Bollard CM. Conway SR, et al. Among authors: jensen wachspress m. Front Immunol. 2022 Jan 18;12:793197. doi: 10.3389/fimmu.2021.793197. eCollection 2021. Front Immunol. 2022. PMID: 35116027 Free PMC article.
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein.
Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM. Keller MD, et al. Among authors: jensen wachspress ma. Blood. 2020 Dec 17;136(25):2905-2917. doi: 10.1182/blood.2020008488. Blood. 2020. PMID: 33331927 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33104167
T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1.
Harris KM, Horn SE, Grant ML, Lang H, Sani G, Jensen-Wachspress MA, Kankate VV, Datar A, Lazarski CA, Bollard CM, Keller MD. Harris KM, et al. Among authors: jensen wachspress ma. Front Immunol. 2020 Oct 5;11:575977. doi: 10.3389/fimmu.2020.575977. eCollection 2020. Front Immunol. 2020. PMID: 33123159 Free PMC article.
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products.
Durkee-Shock J, Lazarski CA, Jensen-Wachspress MA, Zhang A, Son A, Kankate VV, Field NE, Webber K, Lang H, Conway SR, Hanley PJ, Bollard CM, Keller MD, Schwartz DM. Durkee-Shock J, et al. Among authors: jensen wachspress ma. Mol Ther Methods Clin Dev. 2022 Jun 9;25:439-447. doi: 10.1016/j.omtm.2022.04.013. Epub 2022 Apr 29. Mol Ther Methods Clin Dev. 2022. PMID: 35506060 Free PMC article.
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD, Hanley PJ, Chi YY, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai SY, Dávila Saldaña BJ, Hanisch B, Quigg TC, Adams RH, Dahlberg A, Chandrakasan S, Hasan H, Malvar J, Jensen-Wachspress MA, Lazarski CA, Sani G, Idso JM, Lang H, Chansky P, McCann CD, Tanna J, Abraham AA, Webb JL, Shibli A, Keating AK, Satwani P, Muranski P, Hall E, Eckrich MJ, Shereck E, Miller H, Mamcarz E, Agarwal R, De Oliveira SN, Vander Lugt MT, Ebens CL, Aquino VM, Bednarski JJ, Chu J, Parikh S, Whangbo J, Lionakis M, Zambidis ET, Gourdine E, Bollard CM, Pulsipher MA. Keller MD, et al. Among authors: jensen wachspress ma. Nat Commun. 2024 Apr 18;15(1):3258. doi: 10.1038/s41467-024-47057-2. Nat Commun. 2024. PMID: 38637498 Free PMC article. Clinical Trial.
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.
Keller MD, Schattgen SA, Chandrakasan S, Allen EK, Jensen-Wachspress MA, Lazarski CA, Qayed M, Lang H, Hanley PJ, Tanna J, Pai SY, Parikh S, Berger SI, Gottschalk S, Pulsipher MA, Thomas PG, Bollard CM. Keller MD, et al. Among authors: jensen wachspress ma. Nat Commun. 2024 Mar 29;15(1):2749. doi: 10.1038/s41467-024-47056-3. Nat Commun. 2024. PMID: 38553461 Free PMC article.
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
Kinoshita H, Mandava M, Jensen-Wachspress M, Lang H, Joy E, Tanna J, McCann CD, O'Brien S, Burnett S, Shibli A, Hoq F, Bhatia M, Hanley PJ, Dávila Saldaña B, Mahadeo KM, Bollard CM, Keller MD, Abraham A. Kinoshita H, et al. Among authors: jensen wachspress m. Blood Adv. 2023 May 23;7(10):2105-2116. doi: 10.1182/bloodadvances.2022008219. Blood Adv. 2023. PMID: 36516084 Free PMC article.